CEO Joseph Burnett sells 61,843 shares at blended average $17.79 under 10b5-1 plan; holds 191,388 shares plus 270,000 stock options post-sale.
Joseph Burnett, CEO and President, executed 2 sales totaling 61,843 shares for $1,100,463.42 on 2026-06-17 under a pre-arranged 10b5-1 trading plan adopted 2025-06-11—a scheduled, non-discretionary transaction. His non-derivative holdings fell from 253,231 to 191,388 shares, a -24.4% reduction in that portion of his stake, while 270,000 stock options remain outstanding. The sales occurred at $17.79 blended average against a current price of $17.06 and a 52-week high of $30.10, placing execution at -43.3% from the year's peak. ClearPoint Neuro reported latest-quarter revenue of $12,128,000.00 with net income of $-9,552,000.00 and negative full-year profitability, providing limited fundamental support for near-term valuation; the company's 30-day and 90-day price movements of +49.1% and +81.1% respectively suggest recent volatility unmoored from earnings stability. Burnett's cross-ticker track record shows 4 prior sales with average 30-day and 90-day returns of -43.5% and -45.2%, though his 4 same-ticker sales in October 2025 at CLPT recorded 30-day returns ranging from -40.4% to -45.9% and 90-day returns from -42.2% to -47.6%.